Aurobindo Pharma posted a good set of numbers for Q4 and FY16. Total operating income rose 18% (YoY) at Rs.3747 crore. During the quarter, the international sales stood at Rs.3,356 crore and domestic sales at Rs.429 crore, a growth of 89% and 11% respectively. EBITDA for the quarter was up 34.5% and margins rose from 20.7% to 23.5%. Net profit was up 39% at Rs.563 crore.

The formulations business contributed 80% of the total revenues and witnessed 20% YoY growth during the quarter. Thanks to the new launches in the oral and injectable segment and growth in the Natrol business, US formulation business rose 24% and contributed 44% to total revenue. Europe contributed 22% to the topline and grew 9% while ARV and Emerging Markets showed a growth of 23% and 25% respectively. The Active Pharmaceuticals Ingredients business contributed 20% of the total revenues and registered double digit growth of 15% during the quarter.

The company ended FY16 with a consolidated total income at Rs.13,896 crore, up 15% with net profit coming in at Rs.1982 crore, up 26%. During the FY16, the company filed 22 ANDA with USFDA including 20 in the Oral category and 2 in the Injectable category and received the period received highest ever ANDA approvals from USFDA at 58, including 49 Final approvals and 9 tentative approvals. On a cumulative basis the company received 251 approvals from USFDA including 36 tentative* approvals. The company, for FY16 gave out a total dividend of 250%.